TICKERNERD
Menu
URGNURGNHealthcare · Biotechnology

URGN Stock Forecast: UroGen Pharma Ltd. Price Predictions for 2026-2027

Last close, 8 Oct 2026
$37
−9.14% on the day

The 8 Wall Street analysts covering UroGen Pharma Ltd. hold a median 12-month price target of $59 — +59.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 83 of 100 as at 8 Oct 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$2.0B
Ticker Nerd rank
83 / 100
Median analyst target
$59
Analysts covering
8
Revenue$72.5M+199.2% y/y
Operating income$111K
Net income−$14.4M
Free cash flow−$33.1M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−8.8%
1M
−15.6%
YTD
+57.9%
1Y
+113.4%
From 52W high
−26.5%
From 52W low
+125.2%
$16
$50
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

URGN stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores UroGen Pharma Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026
83 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
96
Momentum
94
Value
94
Revisions
91
Quality
67
Volatility
66
Size
37
Accruals
13
Issuance
9

Growth (96): Sales and profits are climbing, and climbing faster than before.

Issuance (9): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

URGN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on URGN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$20$30$40$50$60$70$80Jan 26Apr 26Jul 26Oct 26URGNHigh $75Median $59Low $48

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says8 analysts
7 Buy1 Hold0 Sell
Low $48Median $59High $75

The green dot is the last close — the median target sits +59.5% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 5 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
6 Aug 2026GuggenheimMaintainsBuy$42 → $58
6 Aug 2026HC Wainwright & Co.MaintainsBuy$45 → $75
5 Aug 2026TD CowenMaintainsBuy$50 → $60
21 July 2026GuggenheimMaintainsBuy—
21 July 2026GuggenheimMaintainsBuy$32 → $42
16 July 2026OppenheimerMaintainsOutperformer$40 → $50
16 July 2026OppenheimerMaintainsOutperformer—
3 June 2026HC Wainwright & Co.ReiteratesBuy$45
3 June 2026HC Wainwright & Co.ReiteratesBuy—
18 May 2026HC Wainwright & Co.ReiteratesBuy—
11 May 2026HC Wainwright & Co.MaintainsBuy—
7 May 2026OppenheimerMaintainsOutperform—
31 Mar 2026D. Boral CapitalMaintainsBuy—
2 Mar 2026D. Boral CapitalMaintainsBuy—
23 Jan 2026D. Boral CapitalMaintainsBuy—
5 Jan 2026D. Boral CapitalMaintainsBuy—
27 Oct 2025D. Boral CapitalMaintainsBuy—
27 Oct 2025HC Wainwright & Co.ReiteratesBuy—
3 Oct 2025D. Boral CapitalMaintainsBuy—
19 Aug 2025Piper SandlerInitiatesOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. URGN appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

URGN vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 8 Oct 2026, UroGen Pharma Ltd. returned +113.4% against +16.2% for the S&P 500, dividends included.

URGN vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200250300Jan 26Apr 26Jul 26Oct 26URGNS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

URGN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
5
Analysts cutting
0
Fundamentals

UroGen Pharma Ltd. (URGN) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−13.0×

Cheaper than 95% of US stocks

Price / sales
10.7×

Cheaper than 14% of US stocks

Price / book
−15.8×

Cheaper than 98% of US stocks

EV / EBITDA
−31.9×

Cheaper than 92% of US stocks

Growth & margins
Revenue growth (YoY)
199.2%

Higher than 96% of US stocks

Earnings growth (YoY)
199.2%

Higher than 90% of US stocks

Gross margin
90.9%

Higher than 97% of US stocks

Operating margin
0.2%

Higher than 46% of US stocks

Net margin
−51.7%

Higher than 10% of US stocks

Returns & dividend
Return on equity
145.5%

Higher than 97% of US stocks

Return on assets
−18.1%

Higher than 21% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

UroGen Pharma Ltd. (URGN) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • UroGen Pharma Ltd. has a market value of $2.0B and an enterprise value of $2.1B.

  • Revenue in the twelve months to 30 June 2026: $188.7M. The latest quarter grew 199.2% year on year.

  • Net income over the same four quarters: −$97.6M, a −51.7% net margin.

  • Diluted earnings per share, trailing twelve months: $−1.98.

  • Free cash flow in the twelve months to 30 June 2026: −$159.1M.

  • Shares outstanding: 48.9M.

  • Trailing P/E: −13.0×; forward P/E: 14.8× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • UroGen Pharma Ltd. employs 300 people — $629K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 7 Oct 2026

Data provided by Twelve Data

Peers

URGN vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
URGNUroGen Pharma Ltd.$2.0B
83
ZYMEZymeworks, Inc.$1.8B
63
NVAXNovavax, Inc.$1.8B
58
GENBGenerate Biomedicines, Inc.$1.8B
1
TRVITrevi Therapeutics, Inc.$1.8B
48
XNCRXencor, Inc.$1.8B
83
NTLAIntellia Therapeutics, Inc.$1.8B
53

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own UroGen Pharma Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest URGN news & analysis

Here's Why You Should Add URGN Stock to Your Portfolio Now

Zacks Investment Research · 30 Sept 2026positive

Zacks reports on UroGen's progress toward becoming a commercial-stage growth company, citing surging sales of Zusduri, revenues from Jelmyto, and an advancing pipeline as key strengths. The headline suggests the stock is worth adding to a portfolio.

Why it matters — URGN watchers would care because the article highlights improving commercial performance and pipeline momentum as the company shifts from development toward sustained revenue growth.

Urogen Pharma: Upside After Bladder Cancer Launch

Seeking Alpha · 9 Sept 2026positive

UroGen Pharma has transitioned into a commercial-stage biopharma driven by strong adoption of Zusduri for recurrent non-muscle invasive bladder cancer, which achieved an 80% complete response rate in the ENVISION trial. The company has completed the NDA submission for URGN-103, a next-generation mitomycin-based product positioned to replace Zusduri with manufacturing and convenience advantages.

Why it matters — URGN watchers would care because the company has advanced to commercial stage with a leading bladder-cancer product and is moving forward with a next-generation successor likely to gain approval.

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire · 4 Sept 2026neutral

UroGen Pharma announced it granted inducement restricted stock units (RSUs) to 19 new employees in connection with their employment, as part of its hiring efforts. The new hires will support the commercialization of UroGen's approved products JELMYTO and ZUSDURI and the continued development of its pipeline.

Why it matters — URGN watchers may note that the company is expanding its workforce with experienced hires to support the commercialization of its approved products and the advancement of its pipeline.

UroGen Pharma to Present at Upcoming Investor Conferences

GlobeNewsWire · 2 Sept 2026neutral

UroGen Pharma Ltd. announced that it will present at upcoming investor conferences, according to a press release from its Princeton, New Jersey headquarters on September 2, 2026.

Why it matters — UroGen shareholders may be interested in the company's presentations at investor conferences, which could offer visibility into the company's pipeline and strategy.

FAQ

Frequently asked questions about URGN stock

What is the URGN stock price forecast for 2026-2027?

The 8 Wall Street analysts covering UroGen Pharma Ltd. have a median 12-month price target of $59, with estimates ranging from $48 to $75. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is URGN stock a buy right now?

Of the 8 analysts covering UroGen Pharma Ltd., 7 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks UroGen Pharma Ltd. 83 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank URGN?

As at 8 Oct 2026, UroGen Pharma Ltd. ranks 83 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (96 of 100).

Will URGN stock go up?

No one can know that. What the data says: the median 12-month target from 8 analysts implies +59.5% from the last close, and Ticker Nerd's factor model ranks UroGen Pharma Ltd. 83 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the URGN stock forecast for 2030?

No analyst covering UroGen Pharma Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for URGN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $48 to $75 over the next 12 months.

How has URGN stock performed over the past year?

UroGen Pharma Ltd. returned +113.4% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does UroGen Pharma Ltd. do?

UroGen Pharma Ltd. is a biopharmaceutical company focused on developing and commercializing treatments for urothelial and specialty cancers.

What is the latest news on URGN?

The most recent item we track (Zacks Investment Research, 30 Sept 2026): "Here's Why You Should Add URGN Stock to Your Portfolio Now". Zacks reports on UroGen's progress toward becoming a commercial-stage growth company, citing surging sales of Zusduri, revenues from Jelmyto, and an advancing pipeline as key strengths. The headline suggests the stock is worth adding to a portfolio.

Company

About UroGen Pharma Ltd.

UroGen Pharma Ltd. is a biopharmaceutical company focused on developing and commercializing treatments for urothelial and specialty cancers. The company’s current portfolio centers on its proprietary RTGel reverse-thermal hydrogel platform, which is designed to support localized drug delivery and prolonged contact with urinary tract tissue. Its marketed therapies and pipeline are built around non-surgical, organ-sparing approaches for conditions such as upper tract urothelial cancer and non-muscle invasive bladder cancer. UroGen Pharma Ltd. also advances additional investigational candidates aimed at expanding options in uro-oncology, combining drug formulation expertise with targeted delivery technologies. Headquartered in Princeton, New Jersey, with operations in Israel, the company plays a specialized role in the urology and oncology markets by focusing on treatments tailored to diseases of the urinary tract.

CEO Ms. Elizabeth A. Barrett · 300 employees · United States · https://www.urogen.com